Safety of anticholinergics in patients with benign prostatic hyperplasia

Author： Athanasopoulos Anastasios   Mitropoulos Dionisios   Giannitsas Konstantinos   Perimenis Petros  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.7, Iss.4, 2008-07, pp. : 473-479

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Benign Prostatic Hyperplasia in Patients with Cardiovascular Disease

By Santillo Vincent M.   Lowe Franklin C.  

Drugs & Aging, Vol. 23, Iss. 10, 2006-01 ,pp. : 795-805

Adis International

Access to resources Recommend Favorite

Intraprostatic botulinum toxin A appears to be beneficial for patients with benign prostatic hyperplasia

By  

Inpharma, Vol. 1, Iss. 1565, 2006-01 ,pp. : 8-8

Adis International

Access to resources Recommend Favorite

Efficacy of Low-Dose Tamsulosin in Chinese Patients with Symptomatic Benign Prostatic Hyperplasia

By Li N-C.  

Clinical Drug Investigation, Vol. 23, Iss. 12, 2003-01 ,pp. : 781-787

Adis International

Access to resources Recommend Favorite

Quality-of-Life Assessment in Patients with Benign Prostatic Hyperplasia: Effects of Various Interventions

By Batista-Miranda J-E.  

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1079-1090

Adis International

Access to resources Recommend Favorite

Tamsulosin and floppy iris syndrome in benign prostatic hyperplasia patients

By Tiwari Atul  

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 4, 2006-04 ,pp. : 443-446

Informa Healthcare

Access to resources Recommend Favorite